Lenalidomide — The Phoenix Rises  

Oleh:

List, Alan F.

Jenis: Article from Journal - ilmiah internasional
Dalam koleksi: The New England Journal of Medicine (keterangan: ada di Proquest) vol. 357 no. 21 (Nov. 2007), page 2183.

Ketersediaan

Perpustakaan FK Nomor Panggil: N08.K.2007.06 Non-tandon: 1 (dapat dipinjam: 0) Tandon: tidak ada

Lihat Detail Induk

Isi artikel

Perhaps the darkest memory in modern pharmaceutical history is that of the devastating effects of thalidomide exposure on fetal development. More than four decades later, thalidomide reemerged from the ashes as the prototype for a new proprietary class of drugs with broad pharmacologic effects and promising antineoplastic activity, referred to collectively as immunomodulatory drugs. Thalidomide was first marketed in Europe in the late 1950s as a hypnotic and antiemetic for the treatment of morning sickness during pregnancy. Between 1956 and 1962, approximately 10,000 children were born with severe physical deformities, or phocomelia, as a result of the drug's unrecognized teratogenic . . .

Opini Anda

Klik untuk menuliskan opini Anda tentang koleksi ini!

Kembali